Cross-Talk Signaling Between Non-Small Cell Lung Cancer Cell Lines and Fibroblasts Attenuates the Cytotoxic Effect of Cisplatin

被引:0
作者
Ebid, Nouran [1 ]
Sharaky, Marwa [2 ]
Elkhoely, Abeer [3 ]
El Morsy, Engy M. [3 ]
Saad, Sherif Y. [4 ]
机构
[1] Egyptian Russian Univ, Fac Pharm, Pharmacol & Toxicol Dept, Badr City, Egypt
[2] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Cairo, Egypt
[3] Helwan Univ, Fac Pharm, Pharmacol & Toxicol Dept, Ein Helwan, Cairo, Egypt
[4] Cairo Univ, NCI, Canc Biol Dept, Pharmacol & Expt Oncol Unit, Cairo, Egypt
关键词
apoptosis; cisplatin; co-culture; EGFR; lung cancer; resistance; CARCINOMA-CELLS; GROWTH-FACTOR; RESISTANCE; PROLIFERATION; APOPTOSIS; INDUCE;
D O I
10.1002/jbt.70201
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fibroblasts represent one of the most crucial cell types in the tumor microenvironment (TME), playing a major role in chemoresistance development. This study investigated the ability of fibroblasts to alter the response of non-small cell lung cancer (NSCLC) cell lines to cisplatin exposure. A cytotoxicity assay was performed to determine the IC50 of cisplatin using MTT. The assay was performed on NSCLC cell lines A549 and H1299 monocultures and co-cultures with fibroblasts. The co-culture was performed directly with the HSF cell line and indirectly through conditioned media. The ELISA technique was then used to determine the expression of biochemical markers at various time points of co-culture before and after cisplatin exposure. We observed a time-dependent evolution in the fibroblast-cancer cell interplay. Initially, fibroblast co-culture enhanced the cytotoxic effect of cisplatin, as reflected by decreased IC50 values after 24 h of co-culture. However, prolonged co-culture durations (48-96 h) led to the emergence of cisplatin resistance, coinciding with increased IC50 values and altered expression of key biochemical markers. The findings suggest that fibroblasts undergo a potential identity switch over time, transitioning from a tumor-restrictive to a tumor-promoting phenotype. This switch was associated with the activation of EGFR and FGF signaling pathways, increased expression of angiogenic and metastasis markers (e.g., VEGF, MMP2 & MMP9), and inhibition of apoptosis (e.g., reduced caspase expression). Our results suggest that fibroblasts may initially potentiate the effect of cisplatin on NSCLC cells; however, in a time-dependent manner, fibroblast co-culture attenuates the cytotoxic efficacy of cisplatin.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Capmatinib for non-small cell lung cancer
    Alzofon, N.
    Jimeno, A.
    DRUGS OF TODAY, 2021, 57 (01) : 17 - 25
  • [42] The apoptosis of non-small cell lung cancer induced by cisplatin through modulation of STIM1
    Li, Wenjun
    Zhang, Minhong
    Xu, Lei
    Lin, Danmiao
    Cai, Shaoxi
    Zou, Fei
    EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2013, 65 (7-8) : 1073 - 1081
  • [43] Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer
    Tetsuaki Shoji
    Eiki Kikuchi
    Junko Kikuchi
    Yuta Takashima
    Megumi Furuta
    Hirofumi Takahashi
    Kosuke Tsuji
    Makie Maeda
    Ichiro Kinoshita
    Hirotoshi Dosaka-Akita
    Jun Sakakibara-Konishi
    Satoshi Konno
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 843 - 853
  • [44] Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer
    Shoji, Tetsuaki
    Kikuchi, Eiki
    Kikuchi, Junko
    Takashima, Yuta
    Furuta, Megumi
    Takahashi, Hirofumi
    Tsuji, Kosuke
    Maeda, Makie
    Kinoshita, Ichiro
    Dosaka-Akita, Hirotoshi
    Sakakibara-Konishi, Jun
    Konno, Satoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 843 - 853
  • [45] Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer
    Singh, Shubham
    Saxena, Sangeeta
    Sharma, Himani
    Paudel, Keshav Raj
    Chakraborty, Amlan
    MacLoughlin, Ronan
    Oliver, Brian G.
    Gupta, Gaurav
    Negi, Poonam
    Singh, Sachin Kumar
    Dua, Kamal
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 256
  • [46] Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer
    Randall, J. Michael
    Bharne, Anjali A.
    Bazhenova, Lyudmila A.
    JOURNAL OF THORACIC DISEASE, 2013, 5 (02) : E53 - E57
  • [47] Melatonin and non-small cell lung cancer: new insights into signaling pathways
    Pourhanifeh, Mohammad Hossein
    Sharifi, Mehran
    Reiter, Russel J.
    Davoodabadi, Abdoulhossein
    Asemi, Zatollah
    CANCER CELL INTERNATIONAL, 2019, 19 (1)
  • [48] Picoplatin pharmacokinetics and chemotherapy of non-small cell lung cancer
    Hamilton, Gerhard
    Olszewski, Ulrike
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (10) : 1381 - 1390
  • [49] The increasing role of amphiregulin in non-small cell lung cancer
    Busser, B.
    Coll, J. -L.
    Hurbin, A.
    PATHOLOGIE BIOLOGIE, 2009, 57 (7-8): : 511 - 512
  • [50] Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
    Takezawa, K.
    Okamoto, I.
    Okamoto, W.
    Takeda, M.
    Sakai, K.
    Tsukioka, S.
    Kuwata, K.
    Yamaguchi, H.
    Nishio, K.
    Nakagawa, K.
    BRITISH JOURNAL OF CANCER, 2011, 104 (10) : 1594 - 1601